AR036092A1 - Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende - Google Patents
Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprendeInfo
- Publication number
- AR036092A1 AR036092A1 ARP020102171A ARP020102171A AR036092A1 AR 036092 A1 AR036092 A1 AR 036092A1 AR P020102171 A ARP020102171 A AR P020102171A AR P020102171 A ARP020102171 A AR P020102171A AR 036092 A1 AR036092 A1 AR 036092A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- formula
- methyl
- compound
- alkyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un derivado de benzoxazepina que tiene la fórmula general (1) donde X representa CO o SO2; R1, R2, R3 y R4 se selecciona independientemente entre H, (C1-4)alquilo, (C1-4)alquiloxi, (C1-4)alquiloxi-(C1-4)alquilo, CF3, halógeno, nitro, ciano, NR8R9, NR8COR10 y CONR8R9; R5, R6 y R7 son independientemente H o (C1-4)alquilo; R8 y R9 son independientemente H o (C1-4)alquilo; o bien R8 y R9 forman, junto con el átomo de nitrógeno al cual están unidos, un anillo heterocíclico saturado de 5 o 6 miembros, que opcionalmente contiene otro heteroátomo seleccionado entre O, S - 6NR11; R10 es (C1-4)alquilo; R11 es (C1-4)alquil; A representa el residuo de un anillo heterocíclico saturado de 4-7 miembros que opcionalmente contiene un átomo de oxígeno, estando el anillo opcionalmente sustituido con 1-3 sustituyentes seleccionados entre (C1-4)alquilo, (C1-4)alquiloxi, hidroxi, halógeno u oxo; o una sal farmacéuticamente aceptable del mismo; con la salvedad de que: los compuestos de fórmula (1) don de X es CO; cada uno de R1-R4 es H; y A representa (CH2)3 o (CH2)4; el compuesto de fórmula (1) donde X es CO; R1 es H; R2 es metilo; cada uno de R3-R7 es H; y A representa (CH2)3; el compuesto de fórmula (1) donde X es CO; R1 y R2 son H; R3 es metilo; cada uno de R4-R7 es H; y A representa (CH2)3; el compuesto de fórmula (1) donde X es CO; cada uno de R1-R3 es H; R4 es metilo; cada uno de R5-R7 es H; y A representa (CH2)3; y el compuesto de fórmula (1) donde X es CO; cada uno de R3-R4 es H; R5 es metilo, R6 y R7 son H; y A representa (CH2)3; están excluidos. Su uso para preparar un medicamento, una composición farmacéutica que lo comprende, y el derivado de benzoxazepina de fórmula general (1) anterior donde X, A y R1 a R7 tienen los significados dados anteriormente, excluida la salvedad, el cual se lo usa en terapia. Estos derivados de benzoxazepina son útiles en el tratamiento de enfermedades neurológicas y trastornos psiquiátricos que responden a un aumento de las respuestas sinápticas mediadas por los receptores de AMPA en el sistema nervioso central.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202215 | 2001-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036092A1 true AR036092A1 (es) | 2004-08-11 |
Family
ID=8180450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102171A AR036092A1 (es) | 2001-06-11 | 2002-06-10 | Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7307073B2 (es) |
| EP (1) | EP1399450B1 (es) |
| JP (1) | JP4435561B2 (es) |
| KR (1) | KR100863255B1 (es) |
| CN (1) | CN1257908C (es) |
| AR (1) | AR036092A1 (es) |
| AT (1) | ATE389659T1 (es) |
| AU (1) | AU2002314144B2 (es) |
| BR (1) | BR0210222A (es) |
| CA (1) | CA2450274C (es) |
| CO (1) | CO5550447A2 (es) |
| CZ (1) | CZ300052B6 (es) |
| DE (1) | DE60225689T2 (es) |
| EC (1) | ECSP034891A (es) |
| ES (1) | ES2301651T3 (es) |
| HK (1) | HK1061858A1 (es) |
| HR (1) | HRP20031007A2 (es) |
| HU (1) | HUP0400154A3 (es) |
| IL (2) | IL158905A0 (es) |
| IS (1) | IS2526B (es) |
| MX (1) | MXPA03011563A (es) |
| NO (1) | NO328705B1 (es) |
| NZ (1) | NZ529670A (es) |
| PE (1) | PE20030097A1 (es) |
| PL (1) | PL366721A1 (es) |
| RU (1) | RU2279434C2 (es) |
| SK (1) | SK287150B6 (es) |
| TW (1) | TWI232863B (es) |
| WO (1) | WO2002100865A1 (es) |
| ZA (1) | ZA200309382B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158928A0 (en) | 2001-06-14 | 2004-05-12 | Akzo Nobel Nv | (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES |
| US20110218190A1 (en) * | 2008-11-10 | 2011-09-08 | The Regents Of The University Of California | Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction |
| ES2570569T3 (es) * | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso |
| FR2964969B1 (fr) | 2010-09-16 | 2012-08-24 | Servier Lab | Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN105579575A (zh) | 2013-06-13 | 2016-05-11 | 维罗技术有限责任公司 | 用于治疗代谢失调的组合物和方法 |
| US10821103B2 (en) | 2016-11-07 | 2020-11-03 | Arbutus Biopharma Corporation | Substituted pyridinone-containing trycyclic compounds, and methods using same |
| TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
| TW202010499A (zh) | 2018-04-12 | 2020-03-16 | 加拿大商愛彼特生物製藥公司 | 經取代的吡啶酮之三環化合物的製備方法 |
| EP4121072A1 (en) * | 2020-03-20 | 2023-01-25 | Amathus Therapeutics, Inc. | Cyclic sulfonamide derivatives as trap1 modulators and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1238719A (es) | 1968-11-01 | 1971-07-07 | ||
| CA2450801C (en) | 1992-07-24 | 2009-11-17 | The Regent Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| DE59607274D1 (de) | 1995-01-06 | 2001-08-16 | Hoffmann La Roche | Hydroxymethyl-imidazodiazepine und deren ester |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| DE69831446T2 (de) | 1997-06-09 | 2006-06-14 | Pfizer Prod Inc | Chinazolin-4-on AMPA Antagonisten |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| EE200000468A (et) * | 1998-02-18 | 2002-04-15 | Neurosearch A/S | Ühendid, nende kasutamine ja farmatseutiline kompositsioon |
| US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
-
2002
- 2002-05-31 TW TW091111746A patent/TWI232863B/zh not_active IP Right Cessation
- 2002-06-05 PL PL02366721A patent/PL366721A1/xx not_active IP Right Cessation
- 2002-06-05 RU RU2004100310/04A patent/RU2279434C2/ru not_active IP Right Cessation
- 2002-06-05 JP JP2003503632A patent/JP4435561B2/ja not_active Expired - Lifetime
- 2002-06-05 WO PCT/EP2002/006185 patent/WO2002100865A1/en active IP Right Grant
- 2002-06-05 KR KR1020037016150A patent/KR100863255B1/ko not_active IP Right Cessation
- 2002-06-05 MX MXPA03011563A patent/MXPA03011563A/es active IP Right Grant
- 2002-06-05 AT AT02740691T patent/ATE389659T1/de active
- 2002-06-05 AU AU2002314144A patent/AU2002314144B2/en not_active Expired
- 2002-06-05 ES ES02740691T patent/ES2301651T3/es not_active Expired - Lifetime
- 2002-06-05 CN CNB028116410A patent/CN1257908C/zh not_active Expired - Lifetime
- 2002-06-05 DE DE60225689T patent/DE60225689T2/de not_active Expired - Lifetime
- 2002-06-05 CA CA2450274A patent/CA2450274C/en not_active Expired - Lifetime
- 2002-06-05 IL IL15890502A patent/IL158905A0/xx unknown
- 2002-06-05 US US10/480,623 patent/US7307073B2/en not_active Expired - Lifetime
- 2002-06-05 NZ NZ529670A patent/NZ529670A/en unknown
- 2002-06-05 EP EP02740691A patent/EP1399450B1/en not_active Expired - Lifetime
- 2002-06-05 SK SK1518-2003A patent/SK287150B6/sk not_active IP Right Cessation
- 2002-06-05 HU HU0400154A patent/HUP0400154A3/hu unknown
- 2002-06-05 BR BR0210222-6A patent/BR0210222A/pt not_active Application Discontinuation
- 2002-06-05 CZ CZ20033376A patent/CZ300052B6/cs not_active IP Right Cessation
- 2002-06-10 AR ARP020102171A patent/AR036092A1/es unknown
- 2002-06-10 PE PE2002000495A patent/PE20030097A1/es not_active Application Discontinuation
-
2003
- 2003-11-13 IS IS7036A patent/IS2526B/is unknown
- 2003-11-17 IL IL158905A patent/IL158905A/en not_active IP Right Cessation
- 2003-12-02 ZA ZA200309382A patent/ZA200309382B/en unknown
- 2003-12-04 CO CO03107046A patent/CO5550447A2/es not_active Application Discontinuation
- 2003-12-04 HR HR20031007A patent/HRP20031007A2/xx not_active Application Discontinuation
- 2003-12-10 NO NO20035486A patent/NO328705B1/no not_active IP Right Cessation
- 2003-12-11 EC EC2003004891A patent/ECSP034891A/es unknown
-
2004
- 2004-07-07 HK HK04104926A patent/HK1061858A1/xx not_active IP Right Cessation
-
2007
- 2007-10-25 US US11/924,451 patent/US7504390B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| AR033306A1 (es) | Compuestos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| AR075587A1 (es) | Derivados de bifenilo para el tratamiento de hepatitis c | |
| AR022303A1 (es) | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion | |
| KR927003052A (ko) | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
| AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |